<?xml version='1.0' encoding='utf-8'?>
<document id="30442716"><sentence text="No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone."><entity charOffset="58-68" id="DDI-PubMed.30442716.s1.e0" text="nintedanib" /><entity charOffset="73-84" id="DDI-PubMed.30442716.s1.e1" text="pirfenidone" /><pair ddi="false" e1="DDI-PubMed.30442716.s1.e0" e2="DDI-PubMed.30442716.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30442716.s1.e0" e2="DDI-PubMed.30442716.s1.e1" /></sentence><sentence text="Nintedanib and pirfenidone are approved treatments for idiopathic pulmonary fibrosis (IPF)"><entity charOffset="0-10" id="DDI-PubMed.30442716.s2.e0" text="Nintedanib" /><entity charOffset="15-26" id="DDI-PubMed.30442716.s2.e1" text="pirfenidone" /><pair ddi="false" e1="DDI-PubMed.30442716.s2.e0" e2="DDI-PubMed.30442716.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30442716.s2.e0" e2="DDI-PubMed.30442716.s2.e1" /></sentence><sentence text=" This open-label, two-group trial investigated the pharmacokinetic drug-drug interaction between these two drugs in patients with IPF" /><sentence text="Subjects not treated with antifibrotics at screening (group 1, n=20) received a single nintedanib dose (150 mg) followed by pirfenidone (titrated to 801 mg thrice daily) for 3 weeks, with a further single nintedanib dose (150 mg) on the last day (day 23)"><entity charOffset="87-97" id="DDI-PubMed.30442716.s4.e0" text="nintedanib" /><entity charOffset="124-135" id="DDI-PubMed.30442716.s4.e1" text="pirfenidone" /><entity charOffset="205-215" id="DDI-PubMed.30442716.s4.e2" text="nintedanib" /><pair ddi="false" e1="DDI-PubMed.30442716.s4.e0" e2="DDI-PubMed.30442716.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30442716.s4.e0" e2="DDI-PubMed.30442716.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30442716.s4.e0" e2="DDI-PubMed.30442716.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30442716.s4.e1" e2="DDI-PubMed.30442716.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30442716.s4.e1" e2="DDI-PubMed.30442716.s4.e2" /></sentence><sentence text=" Subjects treated with pirfenidone at screening (group 2, n=17) continued to receive pirfenidone alone (801 mg thrice daily) for 7 days, then co-administered with nintedanib (150 mg twice daily) for a further 7 days, before single doses of both treatments on day 16"><entity charOffset="23-34" id="DDI-PubMed.30442716.s5.e0" text="pirfenidone" /><entity charOffset="85-96" id="DDI-PubMed.30442716.s5.e1" text="pirfenidone" /><entity charOffset="163-173" id="DDI-PubMed.30442716.s5.e2" text="nintedanib" /><pair ddi="false" e1="DDI-PubMed.30442716.s5.e0" e2="DDI-PubMed.30442716.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30442716.s5.e0" e2="DDI-PubMed.30442716.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30442716.s5.e0" e2="DDI-PubMed.30442716.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30442716.s5.e1" e2="DDI-PubMed.30442716.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30442716.s5.e1" e2="DDI-PubMed.30442716.s5.e2" /></sentence><sentence text="In group 1, adjusted geometric mean (gMean) ratios (with/without pirfenidone) were 88"><entity charOffset="65-76" id="DDI-PubMed.30442716.s6.e0" text="pirfenidone" /></sentence><sentence text="6% and 80" /><sentence text="6% for nintedanib area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax), respectively"><entity charOffset="7-17" id="DDI-PubMed.30442716.s8.e0" text="nintedanib" /></sentence><sentence text=" In group 2, gMean ratios (with/without nintedanib) were 97"><entity charOffset="40-50" id="DDI-PubMed.30442716.s9.e0" text="nintedanib" /></sentence><sentence text="2% and 99" /><sentence text="5% for pirfenidone AUC and Cmax, respectively"><entity charOffset="7-18" id="DDI-PubMed.30442716.s11.e0" text="pirfenidone" /></sentence><sentence text=" For all parameters, the 90% confidence intervals included 100%, suggesting similar exposure for administration alone and when co-administered" /><sentence text=" Both treatments were well tolerated" /><sentence text="These data indicate there is no relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone when co-administered in IPF patients"><entity charOffset="87-97" id="DDI-PubMed.30442716.s14.e0" text="nintedanib" /><entity charOffset="102-113" id="DDI-PubMed.30442716.s14.e1" text="pirfenidone" /><pair ddi="false" e1="DDI-PubMed.30442716.s14.e0" e2="DDI-PubMed.30442716.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30442716.s14.e0" e2="DDI-PubMed.30442716.s14.e1" /></sentence><sentence text="" /></document>